Agilon Health, Inc. (NYSE:AGL - Get Free Report) has been given a consensus rating of "Hold" by the fifteen ratings firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $102.25.
Several equities research analysts recently issued reports on AGL shares. Truist Financial set a $112.00 price objective on shares of Agilon Health and gave the stock a "hold" rating in a research report on Thursday, August 6th. Benchmark reiterated a "buy" rating and issued a $140.00 target price (up from $95.00) on shares of Agilon Health in a report on Thursday, August 6th. Weiss Ratings restated a "sell (e+)" rating on shares of Agilon Health in a report on Monday, August 24th. Wells Fargo & Company restated an "overweight" rating and set a $146.00 price target (up from $141.00) on shares of Agilon Health in a report on Tuesday, August 11th. Finally, Barclays set a $111.00 price target on shares of Agilon Health and gave the company an "equal weight" rating in a research report on Thursday, August 6th.
View Our Latest Research Report on Agilon Health
Agilon Health Stock Up 0.5%
Shares of NYSE:AGL opened at $84.57 on Tuesday. Agilon Health has a 52-week low of $7.48 and a 52-week high of $133.04. The stock has a market cap of $1.42 billion, a P/E ratio of -5.93 and a beta of 2.98. The business has a fifty day moving average of $90.21 and a two-hundred day moving average of $77.36. The company has a quick ratio of 1.08, a current ratio of 1.08 and a debt-to-equity ratio of 0.07.
Agilon Health (NYSE:AGL - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $0.14 by $0.90. The business had revenue of $1.49 billion for the quarter, compared to analyst estimates of $1.45 billion. Agilon Health had a negative return on equity of 119.38% and a negative net margin of 3.92%. On average, research analysts expect that Agilon Health will post -2.9 earnings per share for the current year.
Hedge Funds Weigh In On Agilon Health
A number of hedge funds have recently modified their holdings of AGL. North Peak Capital Management LLC raised its stake in shares of Agilon Health by 10.8% during the fourth quarter. North Peak Capital Management LLC now owns 38,139,937 shares of the company's stock worth $26,267,000 after purchasing an additional 3,715,460 shares during the last quarter. State Street Corp acquired a new position in Agilon Health in the 2nd quarter valued at $30,024,000. State of Wyoming increased its stake in Agilon Health by 64.9% in the 4th quarter. State of Wyoming now owns 359,664 shares of the company's stock valued at $248,000 after buying an additional 141,572 shares during the period. Alpine Global Management LLC purchased a new position in Agilon Health during the 4th quarter worth $84,000. Finally, Rubicon Founders LLC acquired a new stake in shares of Agilon Health in the 2nd quarter worth $11,290,448.
About Agilon Health
(
Get Free Report)
Agilon Health, Inc is a healthcare company that helps primary care physicians transition from traditional fee-for-service medicine to value-based care. The company primarily works with independent physician practices that serve older adults, particularly Medicare Advantage members, with the goal of improving care coordination, patient outcomes and the overall healthcare experience.
Agilon provides a technology and services platform designed to support population health management. Its offerings include data analytics, clinical and administrative workflows, practice management support, care coordination resources and assistance with payer contracting.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Agilon Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilon Health wasn't on the list.
While Agilon Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.